vs
Side-by-side financial comparison of Farmland Partners Inc. (FPI) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $20.4M, roughly 1.0× Sight Sciences, Inc.). Farmland Partners Inc. runs the higher net margin — 103.4% vs -20.4%, a 123.8% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -3.5%). Over the past eight quarters, Farmland Partners Inc.'s revenue compounded faster (31.4% CAGR vs 2.9%).
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
FPI vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.7M | $20.4M |
| Net Profit | $21.4M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 103.4% | -20.4% |
| Revenue YoY | -3.5% | 6.9% |
| Net Profit YoY | -63.5% | 64.9% |
| EPS (diluted) | $0.44 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.7M | $20.4M | ||
| Q3 25 | $11.3M | $19.9M | ||
| Q2 25 | $10.0M | $19.6M | ||
| Q1 25 | $10.3M | $17.5M | ||
| Q4 24 | $21.5M | $19.1M | ||
| Q3 24 | $13.3M | $20.2M | ||
| Q2 24 | $11.4M | $21.4M | ||
| Q1 24 | $12.0M | $19.3M |
| Q4 25 | $21.4M | $-4.2M | ||
| Q3 25 | $483.0K | $-8.2M | ||
| Q2 25 | $7.6M | $-11.9M | ||
| Q1 25 | $2.0M | $-14.2M | ||
| Q4 24 | $58.7M | $-11.8M | ||
| Q3 24 | $1.8M | $-11.1M | ||
| Q2 24 | $-2.0M | $-12.3M | ||
| Q1 24 | $1.4M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | — | -18.0% | ||
| Q3 25 | 4.3% | -39.7% | ||
| Q2 25 | 78.2% | -59.6% | ||
| Q1 25 | 20.6% | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | 13.9% | -55.7% | ||
| Q2 24 | -17.9% | -59.2% | ||
| Q1 24 | 11.9% | -76.4% |
| Q4 25 | 103.4% | -20.4% | ||
| Q3 25 | 4.3% | -41.0% | ||
| Q2 25 | 76.3% | -61.0% | ||
| Q1 25 | 19.9% | -80.8% | ||
| Q4 24 | 273.6% | -62.1% | ||
| Q3 24 | 13.5% | -54.9% | ||
| Q2 24 | -17.5% | -57.7% | ||
| Q1 24 | 11.5% | -84.4% |
| Q4 25 | $0.44 | $-0.07 | ||
| Q3 25 | $0.00 | $-0.16 | ||
| Q2 25 | $0.14 | $-0.23 | ||
| Q1 25 | $0.03 | $-0.28 | ||
| Q4 24 | $1.09 | $-0.23 | ||
| Q3 24 | $0.02 | $-0.22 | ||
| Q2 24 | $-0.06 | $-0.25 | ||
| Q1 24 | $0.01 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $161.6M | $42.4M |
| Stockholders' EquityBook value | $467.4M | $63.9M |
| Total Assets | $719.1M | $115.3M |
| Debt / EquityLower = less leverage | 0.35× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | $161.6M | $42.4M | ||
| Q3 25 | $170.4M | $42.4M | ||
| Q2 25 | $193.4M | $42.4M | ||
| Q1 25 | $202.6M | $42.4M | ||
| Q4 24 | $204.6M | $40.0M | ||
| Q3 24 | $394.0M | $37.1M | ||
| Q2 24 | $393.0M | $35.0M | ||
| Q1 24 | $383.0M | $35.0M |
| Q4 25 | $467.4M | $63.9M | ||
| Q3 25 | $457.3M | $64.3M | ||
| Q2 25 | $473.5M | $70.0M | ||
| Q1 25 | $492.2M | $77.6M | ||
| Q4 24 | $494.6M | $87.5M | ||
| Q3 24 | $519.4M | $95.0M | ||
| Q2 24 | $521.5M | $101.6M | ||
| Q1 24 | $526.7M | $109.2M |
| Q4 25 | $719.1M | $115.3M | ||
| Q3 25 | $738.5M | $116.3M | ||
| Q2 25 | $776.7M | $122.0M | ||
| Q1 25 | $810.5M | $129.7M | ||
| Q4 24 | $869.6M | $142.8M | ||
| Q3 24 | $1.0B | $143.6M | ||
| Q2 24 | $1.0B | $149.7M | ||
| Q1 24 | $1.0B | $155.6M |
| Q4 25 | 0.35× | 0.66× | ||
| Q3 25 | 0.37× | 0.66× | ||
| Q2 25 | 0.41× | 0.61× | ||
| Q1 25 | 0.41× | 0.55× | ||
| Q4 24 | 0.41× | 0.46× | ||
| Q3 24 | 0.76× | 0.39× | ||
| Q2 24 | 0.75× | 0.34× | ||
| Q1 24 | 0.73× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.4M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.4M | $-1.8M | ||
| Q3 25 | $-2.0M | $-8.7M | ||
| Q2 25 | $-2.2M | $-7.5M | ||
| Q1 25 | $6.4M | $-11.6M | ||
| Q4 24 | $16.1M | $-3.5M | ||
| Q3 24 | $-4.3M | $362.0K | ||
| Q2 24 | $-6.1M | $-9.5M | ||
| Q1 24 | $11.9M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FPI
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
